Advertisement

Advertisement

lipids

Management of Hypercholesterolemia

Management of Hypercholesterolemia

Teaser: 

Wilbert S. Aronow, MD, FACC, FAHA, AGSF, Department of Medicine, Divisions of Cardiology, Geriatrics, and Pulmonary/Critical Care, New York Medical College, Valhalla, NY, USA.

Randomized, double-blind, placebo-controlled studies and observational studies have documented that statins reduce mortality and major cardiovascular events in high-risk persons with hypercholesterolemia. The Heart Protection Study showed that statins reduced mortality and major cardiovascular events in high-risk persons regardless of the initial level of serum lipids, age, or gender. The updated National Cholesterol Education Program (NCEP) III guidelines state that in very-high-risk patients, a serum low-density lipoprotein (LDL) cholesterol level of <1.81 mmol/L (<70 mg/dL) correct is a reasonable clinical strategy, regardless of age. When a high-risk person has hypertriglyceridemia or low serum high-density lipoprotein cholesterol, consideration can be given to combining a fibrate or nicotinic acid with an LDL cholesterol–lowering drug. For moderately high-risk persons, the serum LDL cholesterol should be reduced to <2.59 mmol/L 2.59 (<100 mg/dL). When LDL cholesterol–lowering drug therapy is used to treat high-risk persons or moderately high-risk persons, the serum LDL cholesterol should be reduced by at least 30–40%. High-risk older persons should be treated with lipid-lowering drug therapy according to NCEP III updated guidelines to reduce cardiovascular morbidity and mortality. The LDL cholesterol should be reduced to <4.14 mmol/L (<160 mg/dL)correct in persons at low risk for cardiovascular disease.
Key words: lipids, statins, lipid-lowering drugs, atherosclerotic vascular disease.

Treatment of High-Risk Older Adults with Lipid-Lowering Drug Therapy

Treatment of High-Risk Older Adults with Lipid-Lowering Drug Therapy

Teaser: 


Wilbert S. Aronow, MD, Department of Medicine, Cardiology, Geriatrics, and Pulmonary/Critical Care Divisions, New York Medical College, Valhalla, NY, USA.

Randomized, double-blind, placebo-controlled studies and observational studies have demonstrated that statins reduce mortality and major cardiovascular events among high-risk older adults with hypercholesterolemia. The Heart Protection Study showed that statins reduced mortality and major cardiovascular events in high-risk persons regardless of the initial level of serum lipids, age, or gender. The updated National Cholesterol Education Program (NCEP) III guidelines state that among very high-risk patients a serum LDL cholesterol level of less than 70 mg/dl (1.8 mmol/l) is a reasonable clinical strategy, regardless of age. When a high-risk person has hypertriglyceridemia or low serum HDL cholesterol, consideration can be given to combining a fibrate or nicotinic acid with an LDL cholesterol-lowering drug. For moderately high-risk persons (having two or more risk factors and a 10-year risk for CHD of 10-20%) the serum LDL cholesterol should be reduced to less than 100 mg/dl (2.6 mmol/l). When LDL cholesterol-lowering drug therapy is used to treat high-risk persons or moderately high-risk persons, the serum LDL cholesterol should be reduced at least 30-40%.
Key words: lipids, statins, lipid-lowering drugs, coronary heart disease, atherosclerotic vascular disease, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides.

Statin Power for Lowering Lipids and Building Better Bones

Statin Power for Lowering Lipids and Building Better Bones

Teaser: 

Christine Oyugi, BSc
Assistant Managing Editor,
Geriatrics & Aging

Statins are the most effective agents for lowering plasma levels of low-density lipoprotein cholesterol (LDL-C) that are currently available and are the mainstay therapy for the treatment of hyperlipidemia. The drugs are the most commonly prescribed agents for this condition because of their efficacy in reducing LDL, their safety, and their excellent tolerability. Recently, several studies have found that statins also have anabolic effects on bone and may substantially reduce the risk of fractures.1

Mundy et al. were the first to discover the bone anabolic properties of statins.2 Prompted by the observation that bone morphogenic protein 2 (BMP2) causes osteoblasts to proliferate, mature, and form new bone, the researchers screened a library of 30,000 natural compounds to find potential bone strengthening drugs. The study showed that lovastatin (a fungal metabolite); fluvastatin, simvastatin and mevastatin specifically activated the BMP-2 promoter. The researchers also found that oral administration of statins (simvastatin or lovastatin) to rats increased the volume of trabecular bone and the rate of bone formation even in ovariectomized mice.